Previous 10 | Next 10 |
LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today anno...
Gainers: Mirum Pharmaceuticals (NASDAQ: MIRM ) +110% . More news on: Mirum Pharmaceuticals, Inc., Axsome Therapeutics, Inc., The Goldfield Corporation, Stocks on the move, Read more ...
Gainers: Genesco (NYSE: GCO ) +33% . More news on: Genesco Inc., Wellesley Bancorp, Inc., Big Lots, Inc., Stocks on the move, Read more ...
Sage Therapeutics SAGE -62% after SAGE-217 flunks MDD study. More news on: Capricor Therapeutics, Inc., Axsome Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Stocks on the move, Read more ...
Solid Biosciences (NASDAQ: SLDB ) reports that the FDA has placed its Phase 1/2 clinical trial, IGNITE DMD , evaluating lead gene therapy candidate SGT-001 in Duchenne muscular dystrophy (DMD) patients on clinical hold after a participant experienced a serious adverse event related to the...
Capricor Therapeutics, Inc. (CAPR) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants AJ Bergmann – Chief Financial Officer Linda Marbán – President and Chief Executive Officer Conference Call Participants Joanne Lee – ...
Capricor Therapeutics (NASDAQ: CAPR ): Q3 GAAP EPS of -$0.43 beats by $0.25 . Revenue of $0.14M (-36.4% Y/Y) misses by $0.08M . Press Release More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR...
LOS ANGELES, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its thi...
Call Scheduled for Thursday, October 24 th at 10:30am Eastern Time LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duche...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...